Back to Results
First PageMeta Content
Asuragen / MicroRNA / RNA / Reata Pharmaceuticals


Mirna Therapeutics Appoints Casi DeYoung as Chief Business Officer Austin, Texas – March 19, 2014 – Mirna Therapeutics (Mirna), a private, clinical stage biopharmaceutical company focused on the development of microR
Add to Reading List

Document Date: 2014-04-02 16:53:00

Open Document

File Size: 94,47 KB

Share Result on Facebook

Company

Reata Pharmaceuticals Inc. / New Enterprise Associates / ODC Therapy Inc. / Pfizer Venture Investments / Merck KGaA / Sofinnova Ventures / Mirna Therapeutics Inc. / EMD Pharmaceuticals Inc. / /

Country

United States / /

Event

Funding / FDA Phase / Employment Change / Judicial Event / /

Facility

Baylor Research Institute / University of Texas / Southwestern University / /

IndustryTerm

stage biopharmaceutical / biotechnology / treatment of cancer / /

MedicalCondition

tumor / cancer / diseases / key tumor / /

MedicalTreatment

immunotherapy / /

Organization

University of Texas at Austin / State’s Emerging Technology Fund / Southwestern University / Baylor Health Care System and Baylor Research Institute / /

Person

Paul Lammers / Mirna Therapeutics (Mirna) / Casi DeYoung / Mirna Therapeutics Appoints Casi DeYoung / Austin / /

Position

Chief Business Officer / president and chief executive officer / vice president of Business Development / director of Global Oncology Operations / /

Product

MRX34 / /

ProvinceOrState

Texas / /

Technology

biotechnology / /

URL

www.mirnarx.com / /

SocialTag